Blankinship & Foster’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$312K Buy
10,940
+89
+0.8% +$2.37K 0.06% 60
2026
Q2
$261K Sell
10,851
-4
-0% -$105 0.05% 68
2026
Q1
$305K Hold
10,855
– – 0.07% 60
2025
Q4
$270K Sell
10,855
-10
-0.1% -$252 0.06% 65
2025
Q3
$277K Buy
10,865
+98
+0.9% +$2.42K 0.06% 62
2025
Q2
$261K Buy
+10,767
New +$251K 0.06% 65
2022
Q3
– Sell
-3,979
Closed -$209K – 54
2022
Q2
$209K Sell
3,979
-212
-5% -$10.8K 0.1% 53
2022
Q1
$217K Hold
4,191
– – 0.09% 51
2021
Q4
$247K Buy
+4,191
New +$208K 0.09% 50

Other funds holding PFE

Blankinship & Foster's PFE Position: Q3 2026 in Review

Blankinship & Foster increased its Pfizer (PFE) stake by 0.82% in Q3 2026, buying an estimated $2.37K and bringing the position to 10,940 shares worth $312K. The position accounts for 0.06% of the portfolio, ranked #60.

Blankinship & Foster first reported a position in PFE in Q4 2021 and has held it in 9 quarters since. 2,916 funds tracked by Wall St. Rank hold PFE as of Q3 2026.

  • Blankinship & Foster held 10,940 shares of Pfizer worth $312K as of Q3 2026.
  • Blankinship & Foster bought 89 Pfizer shares in Q3 2026, an estimated $2.37K.
  • Pfizer made up 0.06% of Blankinship & Foster's portfolio in Q3 2026, its #60 holding.
  • Blankinship & Foster first reported a position in Pfizer in Q4 2021 and has held it in 9 quarters since.
  • 2,916 funds tracked by Wall St. Rank held Pfizer as of Q3 2026.

Based on Blankinship & Foster's 13F filing for Q3 2026, filed 19 Oct 2026.